Status:
COMPLETED
Anti-inflammatory Effect of Agaricus Blazei Murill in Inflammatory Bowel Disease (IBD)
Lead Sponsor:
Oslo University Hospital
Collaborating Sponsors:
ImmunoPharma AS
Conditions:
Ulcerative Colitis
Crohn's Disease
Eligibility:
All Genders
18-60 years
Phase:
PHASE2
PHASE3
Brief Summary
Examine whether daily oral ingestion of a immunomodulatory mushroom extract (AndoSanTM) in patients with ulcerative colitis (UC) and Crohn's disease (CD), experience clinical, biochemical and genetica...
Eligibility Criteria
Inclusion
- moderate disease
Exclusion
- serious disease,
- biological treatment,
- pregnancy.
Key Trial Info
Start Date :
December 1 2011
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2016
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT01496053
Start Date
December 1 2011
End Date
January 1 2016
Last Update
October 8 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Oslo University Hospital, Ulleval
Oslo, Norway, 0407